Troubled KV Pharma hands CEO big raise; CMC buys biologics manufacturing facility; Astellas inks discovery pact on chagas disease;

Conversations on Twitter :

 @FierceBiotech: CIRM favors teamwork with $150M in new stem cell grants. Story | Follow @FierceBiotech

 @JohnCFierce: Deja vu: Dimebon (remember it?) promising in mouse study for Alzheimer's. Scientists want to go back, try again. Release | Follow @JohnCFierce

 @RyanMFierce: Biotech VC deals abound this week: Ultragenyx nailed down $15M, and now Mersana says it's found $27M more with help from deep pockets at NEA. | Follow @RyanMFierce

> KV Pharma may be threatening to file bankruptcy as compounding pharmacies continues to undercut its new drug to prevent premature births, but CEO Greg Divis still warranted a big pay hike. Story

> Remember Dimebon, the experimental Alzheimer's drug that flunked a series of expensive late-stage studies and cost Pfizer a fortune? Scientists at Mt. Sinai say they've put it through mouse tests again--where it proved positive. Now they want to try again and see whether the once-promising compound could work for a certain population. Release

> Astellas Pharma inked a research pact with the Tokyo Institute of Technology in which they will search for new drugs to treat diseases caused by protozoan parasites, such as chagas disease. Story

> CMC Biologics has acquired Xoma's large-scale biologics manufacturing operations in Berkeley, CA. Release

> Australia's Novogen is merging into the U.S.-based devices company Kai Medical. It's selling its glucan tech to TR Therapeutics. Story

Pharma News

 @FiercePharma: WSJ's list of 25 Best CFOs includes 3 drug company execs: Biogen, Allergan, Perrigo. List | Follow @FiercePharma

> Pfizer nears animal health IPO as cost-cutting boosts profits. Story

> Glaxo changes the guard at newly bought HGS. News

> Dendreon to slash 600 more jobs as Provenge sales lag. Article

> FDA nixes new gout use for Regeneron's Arcalyst. Item

Medical Device News

@FierceMedDev: Italy's DiaSorin Group signed a Dx expansion deal with Trivitron for the Indian market. Asian expansion continues. Release | Follow @FierceMedDev

 @MarkHFierce: 23andMe will seek FDA 510(k) clearance for its new personalized DNA test, the company disclosed. Release | Follow @MarkHFierce

 @DamianFierce: Looking to boost its flagging CRM business, Boston Sci snagged CE marks for two MRI-friendly pacemakers. More | Follow @DamianFierce

> Medtronic nabs 510(k) for combination surgical device. Item

> Teleflex hit with Class I recall of venous catheter. Story

Biotech Research News

> Another shot at treating Alzheimer's with Dimebon? Article

> 17 universities win NIH cash for tissue chip/drug safety testing. News

> CIRM favors teamwork with $150M in new stem cell grants. More

Pharma Manufacturing News

 @EricPFierce: It is out with the old and with the new at HGS now that GSK is in charge. More | Follow @EricPFierce

> Plant's IT mess nearly kills AZ growth in new markets. News

> Drug pricing figures into McKesson settlement, earnings. Article

And Finally… Scientists used stem cells to regrow craniofacial tissues in the first human study of its kind. Release